

Key investor information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

**DWS Biotech**


Share class: FC, ISIN: DE000DWS2WY7, Security code: DWS2WY, Currency: EUR

The management company is DWS Investment GmbH, a member of the DWS Group.

Objectives and investment policy

The fund is actively managed. The fund is managed in reference to a benchmark. The objective of the investment policy is to achieve sustained capital appreciation relative to the benchmark (NASDAQ Biotechnology). To achieve this, the fund invests mainly in equities of international companies whose revenues or earnings, as reported in the most recent annual report or other suitable documents of the company, were generated primarily from the biotechnology sector, or whose expenditure was primarily on this sector. Equities of issuers from the health care sector may also be added. In that context, the fund management is responsible for selecting the individual investments. The majority of the fund's securities or their issuers are expected to be components of the benchmark. The fund management will use its discretion to invest in securities and sectors that are not included in the benchmark in order to take advantages of specific investment opportunities. It is expected that the portfolio will not necessarily have a similar

weighting to the benchmark. The positioning of the fund can deviate substantially from the benchmark (e.g., by holding positions that are not contained in the benchmark, as well as by a substantial underweighting or overweighting). The actual leeway in this respect is normally relatively high. In general, a deviation reflects the fund manager's assessment of the particular market situation. This may lead to a more defensive and narrower positioning or to a more active and broader positioning relative to the benchmark. Despite the fact that the fund aims to outperform the benchmark, the potential outperformance might be limited depending on the prevailing market environment (e.g. less volatile market environment) and actual positioning versus the benchmark. The currency of the fund is EUR. Returns and gains are not distributed but are reinvested in the fund. You may request the redemption of shares generally on a daily basis.

Risk and reward profile

The calculation of the risk and reward profile is based on simulated data that cannot be used as a reliable indicator for the future risk profile. This risk indicator is subject to changes; the classification of the fund may change over time and cannot be guaranteed. Even a fund that is classified in the lowest category (category 1) does not represent a completely risk-free investment. The fund is classified in category 7 because its share price may fluctuate very strongly

and the likelihood of both losses and gains may therefore be very high. The following risks could be of particular significance for the fund: The fund invests its assets in selected regions or sectors. This increases the risk that the fund may be negatively influenced by the economic and political conditions in the respective regions or sectors. The fund invests in equities. Equities are subject to strong price fluctuations and thus also to the risk of price decreases. The fund invests in bonds, the value of which depends on whether the issuer is able to afford its payments. The deterioration of credit quality (ability and willingness to repay) may have an adverse affect on the value of the bond.

A more detailed description of risks and other general information can be found in the risk section(s) of the prospectus.

Charges


The charges you pay are used to pay the costs of running the fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

| One-off charges taken before or after you invest | |
|--|--------|
| Entry charge | None |
| Exit charge | None |
| This is the maximum that might be taken out of your money before it is invested (entry charge) and before the proceeds of your investment are paid out (exit charge). | |
| Charges taken from the fund over a year | |
| Ongoing charges | 0.75 % |
| Charges taken from the fund under certain specific conditions | |
| Performance fee | 0.11 % |
| The performance-based fee corresponds to 25% of the amount by which the performance exceeds that of the NASDAQ Biotech Index, up to a maximum of 4% of the average value of the fund. When calculating the performance-based fee, negative carryforwards from the previous five settlement periods are taken into account. Details can be found in the sales prospectus under "Costs". | |

The ongoing charges figure is based on expenses for the fiscal year ending 30.09.2020. It may vary from year to year. It excludes portfolio transaction costs and performance fees, if any.

Additional information on costs can be found in the cost section(s) of the prospectus.

Past performance



Past performance is not a reliable indicator of future performance. All costs and fees that were withdrawn from the FC share class of DWS Biotech were deducted during the calculation. The FC share class of DWS Biotech was launched in 2018.

Practical information

The depositary is State Street Bank International GmbH, Germany. Copies of the prospectus and the periodic reports are available free of charge in the language of this document. The documents as well as other information (including the latest share prices) are available free of charge. The documents are available on your local DWS website or at www.dws.com. Information on the current remuneration policy of the management company, including a description of how remuneration and benefits are calculated is published on the Internet at <https://www.dws.com/footer/Legal-Resources/dws-remuneration-policy?setLanguage=en>. The information will be sent to you in paper form free of charge upon request. The taxation regime applicable to the fund in Germany

may affect your personal tax situation. DWS Investment GmbH may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the sales prospectus. More share classes may be available for this fund - please refer to the relevant section of the prospectus for further details. This fund is authorised in Germany and is regulated by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht). DWS Investment GmbH is authorised in Germany and is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht.

This key investor information is accurate as at 12.02.2021.